Literature DB >> 12467490

Bipolar depression: management options.

Gin S Malhi1, Philip B Mitchell, Shahzad Salim.   

Abstract

Bipolar depression is the predominant abnormal mood state in bipolar disorder. However, despite the key pertinence of this phase of the condition, the focus of research and indeed of clinical interest in the management of bipolar disorder has been mainly on mania. Bipolar depression has been largely neglected, and early studies often failed to distinguish depression due to major unipolar depression from that due to bipolar disorder. Consequently, many treatments used in the management of major depression have been adopted for use in bipolar depression without any robust evidence of efficacy. The selective serotonin reuptake inhibitors (SSRIs), bupropion, tricyclic antidepressants and monoamine oxidase inhibitors are all effective antidepressants in the management of bipolar depression. They are all associated with a small risk of antidepressant-induced mood instability. The mood stabilisers lithium, carbamazepine and valproate semisodium (divalproex sodium) all appear to have modest acute antidepressant properties. Among these, lithium is supported by the strongest data, but the use of lithium in the treatment of bipolar depression as a monotherapeutic agent is limited by its slow onset of action. Recently, there has been a growing body of evidence suggesting that lamotrigine may have particular effectiveness in both the acute and prophylactic management of bipolar depression. Clinical management of bipolar depression involves various combinations of antidepressants and mood stabilisers and is partly determined by the context in which the depressive episode occurs. In general, 'de novo' and 'breakthrough' (where the patient is already receiving medication) bipolar depression may be successfully managed by initiating mood stabiliser monotherapy, to which an antidepressant or second mood stabiliser may be added at a later date, if necessary. Breakthrough episodes of bipolar depression occurring in patients receiving combination therapy (two mood stabilisers or a mood stabiliser plus an antidepressant) require either switching of ongoing medications or further augmentation. If this fails, then novel strategies or ECT should be considered. Bipolar depression is a disabling illness and the predominant mood state for the vast majority of those with bipolar disorder. It therefore warrants prompt management once suitably diagnosed, especially as it is associated with a considerable risk of suicide and in the majority of instances is eminently treatable.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12467490     DOI: 10.2165/00023210-200317010-00002

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  164 in total

Review 1.  Can antidepressants cause mania and worsen the course of affective illness?

Authors:  T A Wehr; F K Goodwin
Journal:  Am J Psychiatry       Date:  1987-11       Impact factor: 18.112

2.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Authors:  M Tohen; T G Jacobs; S L Grundy; S L McElroy; M C Banov; P G Janicak; T Sanger; R Risser; F Zhang; V Toma; J Francis; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-09

3.  Bupropion as a promising approach to rapid cycling bipolar II patients.

Authors:  R F Haykal; H S Akiskal
Journal:  J Clin Psychiatry       Date:  1990-11       Impact factor: 4.384

Review 4.  Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.

Authors:  R Davis; R Whittington; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

5.  Double-blind comparison of bupropion and fluoxetine in depressed outpatients.

Authors:  J P Feighner; E A Gardner; J A Johnston; S R Batey; M A Khayrallah; J A Ascher; C G Lineberry
Journal:  J Clin Psychiatry       Date:  1991-08       Impact factor: 4.384

Review 6.  Treatment of acute bipolar depression: a review of the literature.

Authors:  M Srisurapanont; L N Yatham; A P Zis
Journal:  Can J Psychiatry       Date:  1995-11       Impact factor: 4.356

7.  Psychotic (delusional) depression: a meta-analysis of physical treatments.

Authors:  G Parker; K Roy; D Hadzi-Pavlovic; F Pedic
Journal:  J Affect Disord       Date:  1992-01       Impact factor: 4.839

Review 8.  Valproate in psychiatric disorders: literature review and clinical guidelines.

Authors:  S L McElroy; P E Keck; H G Pope; J I Hudson
Journal:  J Clin Psychiatry       Date:  1989-03       Impact factor: 4.384

9.  Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression.

Authors:  R Bottlender; D Rudolf; A Strauss; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1998       Impact factor: 5.270

10.  Suicidality in patients with pure and depressive mania.

Authors:  S C Dilsaver; Y W Chen; A C Swann; A M Shoaib; K J Krajewski
Journal:  Am J Psychiatry       Date:  1994-09       Impact factor: 18.112

View more
  8 in total

1.  Managing bipolar disorder from urgent situations to maintenance therapy.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 2.  Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis.

Authors:  Eduard Vieta; Marc Valentí
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 3.  Lamotrigine: a review of its use in bipolar disorder.

Authors:  David R Goldsmith; Antona J Wagstaff; Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression.

Authors:  Emma D Deeks; Gillian M Keating
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat.

Authors:  Shagufta Ahmad; Leslie J Fowler; Peter S Whitton
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

7.  Clinical profile and outcome of bipolar disorder patients receiving electroconvulsive therapy: a study from north India.

Authors:  Vineet Bharadwaj; Sandeep Grover; Subho Chakrabarti; Ajit Avasthi; Natasha Kate
Journal:  Indian J Psychiatry       Date:  2012-01       Impact factor: 1.759

8.  The Role of Electroconvulsive Therapy (ECT) in Bipolar Disorder: Effectiveness in 522 Patients with Bipolar Depression, Mixed-state, Mania and Catatonic Features.

Authors:  Giulio Perugi; Pierpaolo Medda; Cristina Toni; Michela Giorgi Mariani; Chiara Socci; Mauro Mauri
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.